CD79b targeting ADC with superior pharmacokinetic profile and anti-tumor activity.

被引：0

作者：

Spycher, Philipp Rene ^{[1
]}

Probst, Philipp ^{[1
]}

Bertrand, Romain ^{[1
]}

Stark, Ramona ^{[1
]}

Santimaria, Roger ^{[1
]}

Grabulovski, Dragan ^{[1
]}

Attinger-Toller, Isabella ^{[1
]}

机构：

[1] Araris Biotech AG, Zurich, Switzerland

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1842

引用

页数：1

共 50 条

[1] A CD79b targeting ADC with superior anti-tumor activity and therapeutic index
Attinger-Toller, Isabella
Probst, Philipp
Bertrand, Romain
Stark, Ramona
Santimaria, Roger
Renard, Emma
Fay, Rachael
Grabulovski, Dragan
Schlereth, Bernd
Spycher, Philipp Rene
CANCER RESEARCH, 2022, 82 (12)
[2] A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC
Schlereth, Bernd
Attinger-toller, Isabella
Probst, Philipp
Bertrand, Romain
Stark, Ramona
Santimaria, Roger
Renard, Emma
Fay, Rachael
Sharman, Jeff P.
Grabulovski, Dragan
Spycher, Philipp
BLOOD, 2022, 140 : 11568 - 11569
[3] Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b
Jahn, Lorenz
Hombrink, Pleun
Hassan, Chopie
Kester, Michel G. D.
van der Steen, Dirk M.
Hagedoorn, Renate S.
Falkenburg, J. H. Frederik
van Veelen, Peter A.
Heemskerk, Mirjam H. M.
BLOOD, 2015, 125 (06) : 949 - 958
[4] THE CHARACTERIZATION OF THE PHARMACOKINETIC PROFILE OF ANTI-TUMOR B (ATB) IN ORAL CANCER PATIENTS
Chen, Jie
Zheng, Zicong
Srinual, Songpol
Sun, Rongjin
Yin, Taijun
Saponjac, Vesna Tumbas
Singh, Rashim
You, Ming
Wong, Stuart
Hu, Ming
DRUG METABOLISM AND PHARMACOKINETICS, 2024, 55
[5] A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Palanca-Wessels, Maria Corinna
Flinn, Ian W.
Sehn, Laurie H.
Patel, Manish
Sangha, Randeep
Czuczman, Myron S.
Salles, Gilles Andre
Morschhauser, Franck
Advani, Ranjana
Press, Oliver W.
Ho, William
Kahn, Robert
Lu, Dan
Su, Zheng
Chu, Yu-Waye
Assouline, Sarit E.
BLOOD, 2012, 120 (21)
[6] In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates
Zheng, Bing
Fuji, Reina N.
Elkins, Kristi
Yu, Shang-Fan
Fuh, Franklin K.
Chuh, Josefa
Tan, Christine
Hongo, Jo-Anne
Raab, Helga
Kozak, Katherine R.
Williams, Marna
McDorman, Elena
Eaton, Dan
Ebens, Allen
Polson, Andrew G.
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (10) : 2937 - 2946
[7] Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile
Momtazi, Amir Abbas
Sahebkar, Amirhossein
CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (28) : 4386 - 4397
[8] A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity
Liu, Lily
Yu, Haijia
Huang, Xin
Tan, Hongzhi
Li, Song
Luo, Yan
Zhang, Li
Jiang, Sumei
Jia, Huifeng
Xiong, Yao
Zhang, Ruliang
Huang, Yi
Chu, Charles C.
Tian, Wenzhi
BMC CANCER, 2015, 15
[9] A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity
Lily Liu
Haijia Yu
Xin Huang
Hongzhi Tan
Song Li
Yan Luo
Li Zhang
Sumei Jiang
Huifeng Jia
Yao Xiong
Ruliang Zhang
Yi Huang
Charles C Chu
Wenzhi Tian
BMC Cancer, 15
[10] HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models
Xu, Yan
Liang, Junqing
Jiang, Shuwen
Yang, Haibin
Zhang, Hui
Mao, Fangfang
Zhu, Jiahuan
He, Jianlin
Yang, Na
Wang, Jian
Zhang, WeiHan
Ren, Yongxin
Su, Weiguo
CANCER RESEARCH, 2024, 84 (06)

← 1 2 3 4 5 →